Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 67

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 67
---
. Travis Mickleserved as the Company’s Chief Executive Officer in 2022 and from January 1, 2023 until January 6, 2023. |

| (3) | Mr. Pascoeserved as the Company’s Chief Executive Officer from January 6, 2023 until June 1, 2023. As noted below, Mr. Pascoe also served as anon-PEONEO in 2022, and his compensation for that year is reflected in the columns entitled “Average Summary Compensation Table Total forNon-PEONEOs” and “Average Compensation Actually Paid toNon-PEONEOs.” |

| (4) | Ms. Christal Mickleserved as the Company’s Interim Chief Executive Officer from June 1, 2023 until October 10, 2023. |

| (5) | Amounts represent the average compensation actually paid to our remaining named executive officers for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated below for each fiscal year. |

<div align='center'>66</div>

Non-PEONEOs

| • |     | 2024: Adrian Quartel, M.D., PPFM, and R. LaDuane Clifton, MBA, CPA |

| • |     | 2023: R. LaDuane Clifton, MBA, CPA, and Joshua Schafer, M.S., MBA |

| • |     | 2022: Richard W. Pascoe, and R. LaDuane Clifton, MBA, CPA |

|                                                                                                                                                                                                           |     |        2024 |     |                 |
| Adjustments                                                                                                                                                                                               |     | Current PEO |     | Average Non-PEO |
| Deduction for Amounts Reported under the “Stock Awards” and “Option Awards” Columns in the Summary Compensation Table for Applicable FY                                                                   |     | -$4,018,000 |     |     -$1,280,180 |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Remain Unvested as of Applicable FY End, determined as of Applicable FY End                                              |     |  $5,838,000 |     |      $1,308,135 |
| Increase based on ASC 718 Fair Value of Awards Granted during Applicable FY that Vested during Applicable FY, determined as of Vesting Date                                                               |     |           - |     |               - |
| Increase/deduction for Awards